PHUN:NASDAQPhunware, Inc. Analysis
Data as of 2026-05-22 - not real-time
$2.02
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Phunware (PHUN) trades at $2.02, sitting just above the computed support of $1.88 and below resistance at $2.30. The 20‑day SMA (2.10) sits above the 50‑day SMA (1.98) but both remain under the 200‑day SMA (2.19), indicating short‑term bullish bias within a longer‑term downtrend. Momentum is neutral with an RSI of 48 and a bearish MACD histogram (-0.018), while volume is increasing, suggesting renewed trader interest. The stock’s beta of 2.48 and a 30‑day volatility of ~59% point to pronounced price swings, and the historical max drawdown of -57% underscores the downside risk. Fundamentally, revenue fell 21% YoY, margins are deeply negative (operating margin -7.4%), and both operating and free cash flow are in the -$10M to -$13M range. However, the company holds $97.9M in cash against modest debt ($0.5M) and trades at a price‑to‑book of 0.44, implying a significant discount to its book value. No dividend is paid, and earnings per share remain negative. Recent material news highlights a leadership transition with Dmitry Kroshka as CEO, the launch of an AI‑enabled “2.0” platform targeting hospitality, and a Q1 loss of $3.2 M. These developments could catalyze top‑line growth but remain unproven.
Overall, PHUN appears undervalued on a balance‑sheet basis yet faces substantial execution risk. Technical indicators are mixed to bearish, and the high beta amplifies downside potential. The strategic pivot to AI and new product rollouts provide a possible growth catalyst, but the company must reverse its cash‑flow negativity and improve profitability to justify a higher valuation.
Overall, PHUN appears undervalued on a balance‑sheet basis yet faces substantial execution risk. Technical indicators are mixed to bearish, and the high beta amplifies downside potential. The strategic pivot to AI and new product rollouts provide a possible growth catalyst, but the company must reverse its cash‑flow negativity and improve profitability to justify a higher valuation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram and RSI near neutral
- Proximity to technical support level
- Increasing volume indicating potential short‑term buying interest
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- New AI‑enabled platform and leadership change could drive revenue growth
- Strong cash position relative to debt
- Undervalued price‑to‑book ratio offering margin of safety
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Persistent negative cash flow and earnings
- High beta and volatility increasing downside risk
- Uncertain timeline for commercial adoption of new products
Key Metrics & Analysis
Financial Health
Revenue Growth-21.20%
P/E Ratio-3.9
ROE-11.04%
ROA-11.65%
Debt/Equity0.58
P/B Ratio0.4
Op. Cash Flow$-11859000
Free Cash Flow$-13130375
Industry P/E39.1
Technical Analysis
TrendNeutral
RSI48.0
Support$1.88
Resistance$2.30
MA 20$2.10
MA 50$1.98
MA 200$2.19
MACDBearish
VolumeIncreasing
Fear & Greed Index91.5
Valuation
Target Price$2.00
Upside/Downside-0.99%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.48
Volatility59.48%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.